High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.
about
Ribavirin: Past, present and futureA pharmacological profile of ribavirin and monitoring of its plasma concentration in chronic hepatitis C infectionEarly ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirinIn Vitro Resistance Study of AG-021541, a Novel Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA PolymeraseReduced Ribavirin Antiviral Efficacy via Nucleoside Transporter-Mediated Drug ResistancePreclinical Characterization of PF-00868554, a Potent Nonnucleoside Inhibitor of the Hepatitis C Virus RNA-Dependent RNA PolymeraseExpert opinion on the treatment of patients with chronic hepatitis CA Novel Class of meso-Tetrakis-Porphyrin Derivatives Exhibits Potent Activities against Hepatitis C Virus Genotype 1b Replicons In VitroHepatitis C: a clinical reviewDiagnosis, management, and treatment of hepatitis C: an updatePegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic ResponseEvolution of interferon-based therapy for chronic hepatitis C.Therapeutic implications of hepatitis C virus resistance to antiviral drugs.Differential impact of adherence to pegylated interferon and ribavirin in the treatment of genotype 1 high viral titer chronic hepatitis CCombination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo.Peginterferon and ribavirin treatment for hepatitis C virus infectionSex differences in drug disposition.Host-based ribavirin resistance influences hepatitis C virus replication and treatment response.Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients.Pharmacokinetics of ribavirin in patients with hepatitis C virus.Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin.Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 InfectionImpact of ribavirin dose on retreatment of chronic hepatitis C patientsInfluence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection.A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C.Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture modelsRibavirin in the treatment of chronic hepatitis C.In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitorA review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin.The utility of therapeutic drug monitoring for ribavirin in patients with chronic hepatitis C--a critical review.Role of ribavirin in HCV treatment response: now and in the future.Taribavirin in the treatment of hepatitis C.Interferon combination therapy for HIV/hepatitis C virus coinfection.Mechanism of action of ribavirin in the treatment of chronic hepatitis C.Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C.Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations.Ribavirin induced hemolysis: a novel mechanism of action against chronic hepatitis C virus infectionThe optimal dose of ribavirin for chronic hepatitis C: From literature evidence to clinical practice: The optimal dose of ribavirin for chronic hepatitis CENT1, a ribavirin transporter, plays a pivotal role in antiviral efficacy of ribavirin in a hepatitis C virus replication cell system.Action of inhibitors on accumulation of processed hepatitis delta virus RNAs.
P2860
Q26775002-5EA8E66D-07DB-4E72-9FA9-A6D16BC570AFQ27023355-C19BCA5B-37FF-4352-8E9F-80B090719395Q27481147-90AA6BF1-5E8C-4C0D-93DD-E6258E08063FQ27485335-F78AA33C-C354-4D2E-9B31-EB1AAE4E279AQ27488307-C6E6A18B-9F1B-4213-86BF-210013472357Q27488428-4978DBF7-7B7E-4F86-9B7D-9CA6EBB4B5A4Q27489903-81F7D64D-6F32-458D-8D79-C6A5410F7609Q27490546-F9FE5F13-4B02-45F3-AEA1-0E5F46FBA80EQ27490788-33801187-6341-4E24-8EC3-04E72501FECFQ29619682-885C1759-D1DC-4AE6-8DAE-B20EC5907A74Q33956478-6271DEEB-FD94-483B-A5BB-43B4FE92C629Q34342092-A430E94F-D428-42C0-A5EC-DF966ED52165Q34409020-8ED869C0-7104-410A-9031-0338CCCFB690Q34415178-810D4EFB-4EDA-4B14-8D87-BA7E53D994F4Q34478823-15AC774D-11A7-45BD-B7AC-3284B4558632Q34521371-D9EE29D3-0F63-4C39-BD3C-1FA66A155DF2Q34635175-BC0F52B9-C8EC-4EA8-9FB0-6C74895CF4D3Q35077712-8F1AE205-AAD2-4C54-B84F-F102B8B7CA50Q35125818-9C884E3C-2427-4153-81DC-EBB351BA5013Q35648745-B7D00A1A-1D8E-415E-ACAB-E313607893FEQ35827938-291C1C15-8807-4012-AAEC-354CC8370339Q36014286-8CCA1D82-70F4-4181-A50B-C2148432D7ECQ36049907-032D39A3-2FC4-42A5-BD72-650C83A24AA3Q36070215-92E00CF5-8113-4D7B-910C-1FA856417FA4Q36306694-76DB8F97-9C04-4027-8EA8-58CB7D378A42Q36399860-6BEDC9BC-ED55-404E-B35A-06545FAF2E58Q37195248-DD3AEB53-69A9-4901-8E8F-D8FB3128FC44Q37263558-D8A56B27-FEB0-4655-A2EC-8D8A8EE460D4Q37614235-8218D7B7-5AB4-42FF-B93E-9E623CBF756CQ37634196-BE6D7FC5-518B-4877-B5F2-FA1C4EA768DFQ37693948-3A76A964-EBF4-46CE-BBBB-C975F1AF04DCQ37919889-7EBFCCBA-85BC-49B4-B3AD-1CF74CAD57D8Q37931258-5F1C66F7-B58E-42CD-B3FD-BCE6DCCCF9A6Q37940977-464B1D8C-9EA2-4EDF-8C8F-0877373FC764Q37975253-2CE6F1FC-FE32-41C2-AC75-D6290425A8D7Q38203823-4B2E49D5-CDB1-41ED-8B98-3366ECFEF5FFQ38282854-ADDA3F4D-B2AF-45AE-A25F-AF24C0100A08Q38915259-0DE85B7F-529A-4085-ADC8-250613335350Q39414574-AAF47139-23C5-4795-B111-474E88FF7ED6Q40305013-E4485EA0-B289-42F4-BB5E-F34A7C1BCD52
P2860
High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
High-dose ribavirin in combina ...... ents with chronic hepatitis C.
@en
High-dose ribavirin in combina ...... ents with chronic hepatitis C.
@nl
type
label
High-dose ribavirin in combina ...... ents with chronic hepatitis C.
@en
High-dose ribavirin in combina ...... ents with chronic hepatitis C.
@nl
prefLabel
High-dose ribavirin in combina ...... ents with chronic hepatitis C.
@en
High-dose ribavirin in combina ...... ents with chronic hepatitis C.
@nl
P2093
P356
P1433
P1476
High-dose ribavirin in combina ...... ients with chronic hepatitis C
@en
P2093
Karin Lindahl
Lars Stahle
Robert Schvarcz
P304
P356
10.1002/HEP.20563
P407
P577
2005-02-01T00:00:00Z